Engineers Gate Manager’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.78M | Buy |
192,500
+113,841
| +145% | +$1.63M | 0.03% | 579 |
|
|
2025
Q4 | $1.12M | Sell |
78,659
-153,493
| -66% | -$1.51M | 0.01% | 975 |
|
|
2025
Q3 | $1.83M | Sell |
232,152
-409,237
| -64% | -$2.91M | 0.02% | 821 |
|
|
2025
Q2 | $3.68M | Buy |
641,389
+479,038
| +295% | +$3.09M | 0.05% | 483 |
|
|
2025
Q1 | $1.32M | Buy |
162,351
+57,943
| +55% | +$536K | 0.02% | 911 |
|
|
2024
Q4 | $984K | Sell |
104,408
-46,314
| -31% | -$481K | 0.02% | 1017 |
|
|
2024
Q3 | $1.61M | Buy |
150,722
+111,985
| +289% | +$1.22M | 0.03% | 748 |
|
|
2024
Q2 | $384K | Sell |
38,737
-54,797
| -59% | -$562K | 0.01% | 1340 |
|
|
2024
Q1 | $1.1M | Buy |
93,534
+66,252
| +243% | +$847K | 0.03% | 771 |
|
|
2023
Q4 | $387K | Buy |
27,282
+6,765
| +33% | +$76.8K | 0.01% | 1307 |
|
|
2023
Q3 | $249K | Sell |
20,517
-54,621
| -73% | -$705K | 0.01% | 1404 |
|
|
2023
Q2 | $944K | Buy |
75,138
+52,966
| +239% | +$629K | 0.04% | 726 |
|
|
2023
Q1 | $246K | Buy |
22,172
+4,199
| +23% | +$51.8K | 0.01% | 1343 |
|
|
2022
Q4 | $219K | Buy |
17,973
+7,854
| +78% | +$88.4K | 0.01% | 1327 |
|
|
2022
Q3 | $106K | Buy |
+10,119
| New | +$113K | 0.01% | 1444 |
|
|
2022
Q2 | – | Sell |
-20,371
| Closed | -$193K | – | 2013 |
|
|
2022
Q1 | $193K | Buy |
+20,371
| New | +$191K | 0.01% | 1630 |
|
|
2021
Q4 | – | Sell |
-23,466
| Closed | -$224K | – | 2100 |
|
|
2021
Q3 | $224K | Sell |
23,466
-82,079
| -78% | -$840K | 0.01% | 1375 |
|
|
2021
Q2 | $1.02M | Buy |
105,545
+84,545
| +403% | +$825K | 0.07% | 436 |
|
|
2021
Q1 | $207K | Buy |
21,000
+454
| +2% | +$7.03K | 0.01% | 1580 |
|
|
2020
Q4 | $474K | Sell |
20,546
-48,290
| -70% | -$988K | 0.02% | 1016 |
|
|
2020
Q3 | $972K | Buy |
68,836
+55,178
| +404% | +$804K | 0.05% | 626 |
|
|
2020
Q2 | $206K | Buy |
+13,658
| New | +$166K | 0.01% | 1434 |
|
|
2020
Q1 | – | Sell |
-98,197
| Closed | -$956K | – | 1690 |
|
|
2019
Q4 | $956K | Buy |
98,197
+86,197
| +718% | +$789K | 0.04% | 664 |
|
|
2019
Q3 | $96K | Buy |
+12,000
| New | +$130K | ﹤0.01% | 1314 |
|
|
2019
Q2 | – | Sell |
-22,900
| Closed | -$311K | – | 1226 |
|
|
2019
Q1 | $311K | Buy |
+22,900
| New | +$280K | 0.02% | 731 |
|
|
2017
Q4 | – | Sell |
-10,300
| Closed | -$155K | – | 762 |
|
|
2017
Q3 | $155K | Buy |
+10,300
| New | +$136K | 0.01% | 653 |
|
|
2016
Q1 | – | Sell |
-17,671
| Closed | -$171K | – | 729 |
|
|
2015
Q4 | $171K | Buy |
+17,671
| New | +$159K | 0.01% | 614 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Engineers Gate Manager's FOLD Position: Q1 2026 in Review
Engineers Gate Manager increased its Amicus Therapeutics (FOLD) stake by 145% in Q1 2026, buying an estimated $1.63M and bringing the position to 192,500 shares worth $2.78M. The position accounts for 0.03% of the portfolio, ranked #579.
Engineers Gate Manager first reported a position in FOLD in Q4 2015 and has held it in 27 quarters since. The position peaked at $3.68M in Q2 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Engineers Gate Manager held 192,500 shares of Amicus Therapeutics worth $2.78M as of Q1 2026.
- Engineers Gate Manager bought 113,841 Amicus Therapeutics shares in Q1 2026, an estimated $1.63M.
- Amicus Therapeutics made up 0.03% of Engineers Gate Manager's portfolio in Q1 2026, its #579 holding.
- Engineers Gate Manager first reported a position in Amicus Therapeutics in Q4 2015 and has held it in 27 quarters since.
- Engineers Gate Manager's Amicus Therapeutics position peaked at $3.68M in Q2 2025.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Engineers Gate Manager's 13F filing for Q1 2026, filed 15 May 2026.